96-week results of a pilot study of Abacavir/Lamivudine and raltegravir in antiretroviral-Naïve HIV-1-infected patients: The SHIELD trial

HIV Clinical Trials

Volumn 12, Issue 4, 2011, Pages 228-233

  Young, B ^a,b   Vanig, T ^c   Dejesus, E ^d   Hawkins, T ^e   St Clair, M ^f   Stancil, B ^f   Ha, B ^e  

^a Rocky Mountain CARES/DIDC   (United States)

^b Health Connections International   (Netherlands)

^c Spectrum Medical Group   (United States)

^d ORLANDO IMMUNOLOGY CENTER   (United States)

^e Southwest CARE Center   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REBOUND; RNA ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD;

DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; PYRROLIDINONES;

EID: 80455129908     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/HCT1204-228     Document Type: Letter

References (5)

1. Young B, Vanig T, DeJesus E, et al. A pilot study of abacavir/ lamivudine and raltegravir in antiretroviral-naïve HIV-1- infected patients: 48-week results of the SHIELD trial. HIV Clin Trials. 2010;11:260-269.
2. Young B, Fransen S, Greenberg KS, et al. Transmission of integrase strand-transfer inhibitor, multi-drug resistant HIV-1: Case report and natural history of response to raltegravir-containing antiretroviral therapy. Antivir Ther. 2011;16(2):253-256.
3. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52: 350-356.
4. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naïve HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39-48.
5. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.